Fortress Biotech 9.375% Series A Preferred Stock (FBIOP)

• Market cap: $45.8M
• 1 day: -2.48%
• 5 days: -1.84%
• 1 month: 22.66%
• 3 months: 44.7%
• 6 months: 57.85%
• Year to date: 31.59%
• 1 year: 99.55%
• 5 years: -42.59%
• 10 years: -44.87%
• Sector: Healthcare
• Industry: Biotechnology

About: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Employees: 101